#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Is It Necessary to Discontinue Dupilumab in Patients with Atopic Dermatitis During the COVID-19 Pandemic?

Italian authors described their experiences with remote treatment of 200 atopic dermatitis (AD) patients using dupilumab during the COVID-19 pandemic outbreak in spring 2020. Observations from clinical practice, published data, and pathophysiological considerations do not suggest an increased risk of SARS-CoV-2 infection in AD patients receiving this biological treatment.
Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 14. 12. 2020

News Early Implementation of Highly Effective Therapy for Multiple Sclerosis

The ongoing debate about changing the approach to treating relapsing-remitting multiple sclerosis (RRMS) from an escalation strategy to the early implementation of highly effective therapy (HET) is based on the documented high inflammatory activity of the disease in its early stages and the concept of a therapeutic window for its suppression shortly after diagnosis. We bring you a summary of several recent pieces of information about the benefits and safety of HET as an initial treatment for RRMS.
Source: Neurology - Multiple Sclerosis 20. 9. 2023

News Pediatric Immune Thrombocytopenia Does Not Overlap with Adult ITP

Immune thrombocytopenia (ITP) is a highly heterogeneous disease characterized by various bleeding manifestations and different needs for treatment or likelihood of remission. The difference is accentuated in terms of the disease course between children and adult patients.
Source: Immune Thrombocytopenia 8. 6. 2020

News Long-term effect of the triple combination of perindopril, indapamide, and amlodipine on left ventricular hypertrophy in hypertension

A recent open-label interventional study aimed to describe the long-term effect of a fixed triple combination of perindopril, indapamide, and amlodipine compared to a free combination of a RAAS inhibitor, diuretic, and calcium channel blocker on the reduction of left ventricular hypertrophy (LVH) in hypertensive outpatients.
Source: ACE inhibitory 18. 4. 2021

News Venous Insufficiency of the Lower Extremities –⁠ A Diverse Range of Risks, Manifestations, and Complications

Although initially often asymptomatic, chronic venous insufficiency includes a variety of symptoms. Some of its manifestations can be irreversible, increasing the socio-economic burden that this disease, especially in its advanced stages, represents. German authors have summarized the latest findings on the epidemiology, risks, pathogenesis, manifestations, and complications of CVI in their review.
Source: Venous Insufficiency 20. 11. 2020

News Current Reimbursement Conditions for the Dual Inhibitor IL-4/IL-13 Dupilumab

The biologic dupilumab is approved for the treatment of several diseases with type 2 inflammation. What is the current reimbursement situation in key indications? We summarize in the following brief overview.
Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 4. 3. 2024

News Experience with Proton Radiotherapy for Anal Canal Carcinoma in Real Czech Practice

Radiotherapy has the potential to achieve complete tumor regression in patients with anal carcinoma, representing an effective alternative to radical surgery. However, it is associated with significant acute and late toxicity. Proton radiotherapy has shown better dose distribution in dosimetric studies compared to conventional photon therapy. What are the experiences with this treatment modality in real practice?
Source: Proton Radiotherapy 16. 10. 2023

News Pregabalin can be chosen as the 1st line treatment for postherpetic neuralgia

The efficacy of pregabalin in patients with postherpetic neuralgia has been demonstrated in 4 multicenter randomized double-blind placebo-controlled studies.
Source: Neuropathic Pain 22. 6. 2020

News Tapentadol Hydrochloride in Clinical Practice –⁠ To Whom, When, How, and Why?

Thanks to its specific properties, tapentadol hydrochloride ranks among the most effective opioids for managing chronic non-cancer pain. Unlike most opioids, it also exhibits an analgesic effect in neuropathic pain. The following brief overview summarizes its mechanism of action and resulting benefits, reimbursement and prescription conditions, its place in the pain management algorithm, and examples of its application in clinical practice.
Source: Updates in Pain Treatment 12. 10. 2023

News Impact of Smoking on Postoperative Wound Healing

Modern surgery aims to shorten postoperative hospitalization by providing faster recovery from surgical consequences. Due to principles of asepsis and antisepsis, wound healing has significantly improved and the occurrence of infectious complications has decreased. However, smoking significantly prolongs recovery. We present new study results comparing wound healing in smokers and non-smokers.
Source: Wound Healing 1. 4. 2020

News Impact of Thyroid Dysfunction on the Cardiovascular System in Elderly Patients

The incidence of thyroid disease increases with age. In the Czech Republic, up to 5% of the population suffers from hypothyroidism, and the prevalence of hyperthyroidism is estimated at 0.2-1%. The following text discusses the impact of these thyroid disorders on the cardiovascular (CV) system in elderly patients.
Source: Thyroid Disorders 2. 11. 2020

News Osteonecrosis of the Jaw Associated with Antiresorptive Pharmacotherapy in Oncological Patients

Antiresorptive pharmacotherapy in the form of bisphosphonates and denosumab is associated, according to current knowledge, with the risk of jaw osteonecrosis, especially following dental procedures such as tooth extractions. The aim of the newly published systematic review was therefore to evaluate the incidence of this complication following dental extractions in connection with the administration of antiresorptive medication and to identify risk factors for jaw osteonecrosis in oncological patients.
Source: Prevention of Bone Events 8. 6. 2023

News End of Unnecessary Biopsies? Prostate Health Index (PHI) in Detecting Aggressive Carcinoma

The Prostate Health Index (PHI) combines the results of three blood-derived parameters: total PSA (tPSA), free PSA (fPSA), and [-2]proPSA (p2PSA) into a single numerical score: PHI = (p2PSA / fPSA × √tPSA). It is a marker used to differentiate patients indicated for prostate biopsy, enabling prediction of cancer aggressiveness and helping to choose the optimal course of action for a particular patient. Its benefit in distinguishing aggressive prostate cancer from indolent tumors or benign lesions was already proven in 2015.
Source: Prostate Health Index 2. 2. 2020

News Current Approaches to COPD Therapy According to GOLD Recommendations and in the Conditions of Czech Practice

Chronic Obstructive Pulmonary Disease (COPD) represents a significant global cause of morbidity and mortality with a high prevalence that is expected to increase significantly in the coming years. Since it is a preventable and treatable disease, active therapy, which is globally guided by international recommendations based on the GOLD strategy, plays an important role. However, in the following article, we will also place these recommendations in the current context of care for these patients in the Czech Republic.
Source: Treatment of Asthma and COPD 15. 11. 2022

News Low-Molecular-Weight Heparins in Thromboprophylaxis After Major Orthopedic and Traumatological Procedures According to Current Recommendations

Patients after major orthopedic and traumatological procedures are at high risk of thromboembolic disease. This is especially true for people undergoing hip and knee replacement or patients with a proximal femur fracture and severe lower limb injury. The routine implementation of pharmacological thromboprophylaxis, such as low-molecular-weight heparins, is currently the gold standard in perioperative care in these cases.
Source: Thromboprophylaxis 20. 6. 2022

1 … 86 87 88 89 90 … 667
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#